Backed by expert scientific and medical advisors and dedicated to our stockholders, the Trevi leadership team is highly engaged and experienced in life science clinical development, successful commercialization, and building value.
Board of Directors
David Meeker, M.D. – Chairman
James Cassella, Ph.D.
James Cassella, Ph.D. has served as a member of our board of directors since February 2020. Dr. Cassella has served as Chief Development Officer for Concert Pharmaceuticals, Inc., a publicly-traded biotechnology company, since February 2015. Prior to joining Concert, Dr. Cassella served as Executive Vice President, Research and Development and Chief Scientific Officer of Alexza Pharmaceuticals, Inc. from July 2012 to January 2015 and served as its Senior Vice President, Research and Development from June 2004 to July 2012. From April 1989 to April 2004, Dr. Cassella held various management positions, including Senior Vice President of Clinical Research and Development at Neurogen Corporation, a publicly traded biotechnology company. Prior to Neurogen, Dr. Cassella was Assistant Professor of Neuroscience at Oberlin College. Dr. Cassella received a Ph.D. in Physiological Psychology from Dartmouth College, completed a postdoctoral fellowship in the Department of Psychiatry at the Yale University School of Medicine and received a B.A. in Psychology from the University of New Haven.
Co-Founder, President and CEO
Jennifer Good is our co-founder and has served as a member of our board of directors and as our President and Chief Executive Officer since our inception in March 2011. Previously, Ms. Good served at Penwest Pharmaceuticals, where she held various positions including President and Chief Executive Officer, Chief Operating Officer and Chief Financial Officer. Ms. Good currently serves on the board of Rhythm Pharmaceuticals, Inc., a publicly traded rare disease company. Ms. Good previously served on the board of Juniper Pharmaceuticals, Inc., a publicly traded healthcare company, from September 2017 until it was acquired in August 2018. Ms. Good currently serves as a board member of the Friedreich’s Ataxia Research Alliance (FARA), a patient advocacy group advancing treatments for the cure of Friedreich’s Ataxia, and is the Treasurer for a non-profit organization, Newtown Youth and Family Services, which provides mental health services and programs to support the community. Ms. Good is also one of the board members of the BIO Emerging Companies Section (ECS) Governing Board, a board member of the Executive Women in Bio, CT Chapter and is a Co-Chair of the New Haven Regional Bioscience Collaborative. Ms. Good received a Bachelor of Business Administration degree with a concentration in accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive.
Chief Financial Officer
Lisa Delfini has served as our Chief Financial Officer since August 2021. Ms. Delfini joins Trevi with 30 years of experience in the financial sector. Her background includes helping public and private companies with finance transformation and preparing for and executing capital raising activities, acquisitions, and other complex financial and accounting matters. As a Financial Accounting and Advisory Services Partner at Marcum LLP, Ms. Delfini led a team of professionals who provided advisory services on financial activities to companies. In this role, she served as interim CFO, CAO or controller for companies in multiple sectors, including pharmaceuticals. Previously, Ms. Delfini worked at General Electric where she was the Global Controller for the GE Corporate Technical Center of Excellence (TCOE) and then became the Global Controller for GE Industrial Solutions. Ms. Delfini began her career at Deloitte & Touche LLP where she worked for 16 years and completed her time there as a Client Service Partner. She holds a B.S. in Accounting from Lehigh University and is a Certified Public Accountant in the State of Connecticut.
David Clark, M.D., MRCP
Chief Medical Officer
David Clark, MD, MRCP has served as our Chief Medical Officer since November 2022. Dr. Clark joined Trevi with over 25 years of global clinical development experience in big pharma and biotech. Most recently, Dr. Clark served as Chief Medical Officer at Allena Pharmaceuticals, leading the Company’s clinical development, regulatory and medical affairs teams. Prior to that, he served as Chief Medical Officer for various companies, including Aldeyra Therapeutics, Wilson Therapeutics, and NormOxys. As Chief Medical Officer, Dr. Clark has strategized and supported teams from clinical translation through Phase 3. He has also held senior leadership positions at TransTech Pharma, Pfizer, SmithKline Beecham, and GlaxoSmithKline. Dr. Clark holds a Bachelor of Medicine and Surgery (MD) from the University of Edinburgh Medical School, and a Membership of the Royal College of Physicians (MRCP). Dr. Clark also completed a research fellowship in respiratory medicine in the United Kingdom.
Thomas Sciascia, M.D.
Co-Founder, Chief Science Officer
Thomas Sciascia, M.D., is our co-founder and Chief Science Officer. Previously, Dr. Sciascia was the Senior Vice President of Clinical Development and Regulatory and Chief Medical Officer at Penwest. Prior to joining Penwest, Dr. Sciascia worked at Quintiles, Inc. as a consultant to pharmaceutical and biotechnology companies. Dr. Sciascia also worked as Medical Director at Transkaryotic Therapies, Inc. (later acquired by Shire Pharmaceuticals Group plc). Dr. Sciascia received a B.S. in biology from the Massachusetts Institute of Technology and a medical degree from Columbia University. He is a board-certified neurologist licensed to practice medicine in the state of Massachusetts.
Farrell Simon, Pharm.D.
SVP, Commercial & Strategy
Farrell Simon, Pharm.D. is currently the SVP, Head of Commercial and Strategy for Trevi Therapeutics. He is an experienced general manager who has successfully led operating plans for brands of varying sizes and geographies, and has worked across the lifecycle of development from marketed products to early commercial development assets. Prior to joining Trevi, Farrell spent 10 years at Pfizer in commercial and operations roles. He last served as Chief of Staff to the Group President of Biopharma at Pfizer and was a member of the Biopharma executive leadership team. This leadership team managed $38B in revenue and the medicines and vaccines within these business units addressed patient needs in oncology, rare disease, inflammation & immunology, primary care, infectious diseases, and preventative care with vaccines. Prior to Pfizer, Farrell gained general management, marketing, and medical affairs experience at Procter & Gamble. He is founder and CEO of The Simon Cancer Foundation and is on the board of directors for the Greater New Haven Chamber of Commerce. He previously held positions on the advisory boards for the Business School and the College of Pharmacy at the University of Florida. Farrell holds both an M.B.A. and a Pharm.D. from the University of Florida.
VP, Medical Affairs
Danine Summers is our Vice President of Medical Affairs at Trevi. Danine has over 35 years of experience in the pharmaceutical industry, the last 20 years in dermatology and more recently in pulmonology. She started her career in field sales with Merck Sharp & Dohme and then moved on to American Scientific Products and Roche Labs. While at Roche Danine completed her MBA and transitioned from sales to marketing. She has 18 years of experience in various areas of Marketing including time with FCB Healthcare (clients included Syntex, Gilead, Allergan and Neutrogena) and Connetics Pharmaceuticals, where she built out the marketing department for the company. For the past 15 years Danine has focused on building the Medical Affairs function in companies where it did not previously exist. This include work done at Medicis, Anacor Pharmeceuticals and Menlo Therapeutics. Further, she has led and/or participated in over 10 product launches in her career. Danine joined Trevi Therapeutics in early 2020.
Katherine Takaki, Ph.D.
VP, Global Regulatory Affairs
Katherine Takaki, Ph.D. is the VP of Global Regulatory Affairs at Trevi. She has over 30 years of pharmaceutical industry experience in regulatory strategy, global project and team management, and drug discovery. Before joining Trevi, Katherine served as Vice President, Global Regulatory Affairs at Iterum Therapeutics where she helped build out the regulatory group to support the Company’s regulatory strategy and operations. Prior to that, she held leadership positions at Bristol Myers Squibb supporting multiple therapeutic areas and covering all stages of drug discovery and development. She was the global project manager for the team that developed Baraclude for the treatment of hepatitis B and launched it in markets worldwide. She was subsequently the Group Director, Head of Regulatory Strategy Marketed Products at Bristol Myers Squibb. Katherine holds a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology and a B.S. in Chemistry from the University of Hawaii at Manoa.
VP, Clinical Operations
Paula Buckley is the VP of Clinical Operations at Trevi. She has almost 35 years pharmaceutical industry experience in Analytical Chemistry, Quality Assurance and Clinical Operations. Before joining Trevi Paula served as VP Quality Assurance/Control at Penwest, as well as several leadership roles in Quality Assurance and Control in companies such as Bayer, Anesiva and I-Health. During her years at Bayer, she worked in leadership roles in Analytical Chemistry in several therapeutic areas. Paula received her Bachelor of Science degree at Southern CT State University in 1987.